Drug Profile
Bimatoprost ophthalmic solution - Aequus Pharmaceuticals
Alternative Names: Bimatoprost 0.03% - Aequus Pharmaceuticals; Pr Vistitan; Vistitan; Zimed; ZimedPFLatest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Sandoz Canada
- Developer Aequus Pharmaceuticals; Sandoz Canada
- Class Amides; Antiglaucomas; Lipids; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2alpha receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 30 May 2023 Aequus Pharmaceuticals and Medicom Healthcare plan to launch bimatoprost 0.03% ophthalmic solution preservative free in Canada (Ophthalmic, Liquid), in Q4 2023
- 20 Dec 2022 Zimed ® PF (Bimatoprost 0.03%) receives notice of compliance in Canada (Ophthalmic, Liquid)
- 16 May 2017 Chemical structure information added